Revealed: The true scale of weight-loss drug use in ireland

"Five per cent of respondents said they are using - or previously used - GLP-1 weight-loss drugs like Ozempic, Mounjaro and Wegovy."

"Some 55pc of people said cost was a barrier to use, while 12pc said it wasn't, and a further 33pc said they "don't know"."

Five percent of respondents reported using or previously using GLP-1 weight-loss drugs such as Ozempic, Mounjaro, and Wegovy. Cost emerged as a key factor affecting use. Fifty-five percent said cost was a barrier to using the medication. Twelve percent said cost was not a barrier. Thirty-three percent said they did not know whether cost would affect their use. The poll also reflects differing personal experiences among women who reported positive effects from the medication.

Read at Independent